financetom
Business
financetom
/
Business
/
Market Chatter: Trump to Make Pfizer Drug-Pricing Deal Announcement, Unveil 'TrumpRx'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Trump to Make Pfizer Drug-Pricing Deal Announcement, Unveil 'TrumpRx'
Sep 30, 2025 8:36 AM

11:00 AM EDT, 09/30/2025 (MT Newswires) -- The Trump administration is expected to announce Tuesday that Pfizer ( PFE ) plans to lower prices for several of its medications in the US, The Washington Post reported.

Separately, the White House is also expected to unveil a direct-to-consumer website, dubbed TrumpRx, where Americans can buy prescription drugs, The Wall Street Journal reported Tuesday.

Pfizer ( PFE ) did not immediately reply to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 24.36, Change: +0.50, Percent Change: +2.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Starbucks Faces Near-Term Pressures, But Long-Term Outlook Remains Positive, UBS Says
Starbucks Faces Near-Term Pressures, But Long-Term Outlook Remains Positive, UBS Says
Apr 23, 2024
03:08 PM EDT, 04/23/2024 (MT Newswires) -- Starbucks' ( SBUX ) 2024 outlook will likely be affected by near-term pressures, but it remains well-positioned in the long term due to strong customer brand affinity and an attractive growth profile, UBS said in a note emailed Tuesday. Challenges in the US stem from protests related to Middle East conflict and pressure...
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Apr 23, 2024
Tuesday, Incyte Corporation ( INCY )  agreed to acquire Escient Pharmaceuticals for $750 million. Escient’s pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), and EP547, a first-in-class oral MRGPRX4 antagonist. “EP262 and EP547 are complementary additions to our portfolio, providing an opportunity to leverage our expertise, address the needs of patients with inflammatory diseases, and additional potential launch opportunities starting...
--Street Color: L3Harris Technologies to Reportedly Eliminate 5% of Workforce in 2024
--Street Color: L3Harris Technologies to Reportedly Eliminate 5% of Workforce in 2024
Apr 23, 2024
03:10 PM EDT, 04/23/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 208.32, Change: +0.18, Percent...
Microsoft Launches Lightweight Generative AI Models
Microsoft Launches Lightweight Generative AI Models
Apr 23, 2024
03:12 PM EDT, 04/23/2024 (MT Newswires) -- Microsoft ( MSFT ) said Tuesday it has launched an artificial intelligence model that can be trained on smaller amounts of data. The Phi-3-mini, a so-called small language model, was made available on Hugging Face and Ollama and does not require as much computing resource as its large language model counterparts, according to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved